Abstract
Cardiovascular disease is the leading cause of morbidity and mortality in the Western world. However, it appears that currently available risk assessment tools often underestimate risk, especially for patients in the intermediate-risk category. Considering the socioeconomic cost, it is imperative to correctly identify patients in the intermediate-risk category who would benefit from more aggressive treatment. A plethora of experimental and observational studies provide support that lipoprotein associated phospholipase A2 (Lp- PLA2) and secretory phospholipases A2 (sPLA2) as well as high sensitivity C-reactive protein (hsCRP) are useful biomarkers of cardiovascular risk. Particularly, Lp-PLA2) has also been addressed as pharmacological target and we are eagerly awaiting the results of ongoing phase III clinical trials. In this review we discuss the current literature regarding the pros and cons of these biomarkers.
Keywords: Atherosclerosis, biomarkers, cardiovascular disease, hsCRP, inflammation, Lp-PLA2, PAF-acetylhydrolase, sPLA2.
Current Pharmaceutical Design
Title:Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Volume: 19 Issue: 21
Author(s): Elisavet Moutzouri, Vasilis Tsimihodimos and Alexandros D. Tselepis
Affiliation:
Keywords: Atherosclerosis, biomarkers, cardiovascular disease, hsCRP, inflammation, Lp-PLA2, PAF-acetylhydrolase, sPLA2.
Abstract: Cardiovascular disease is the leading cause of morbidity and mortality in the Western world. However, it appears that currently available risk assessment tools often underestimate risk, especially for patients in the intermediate-risk category. Considering the socioeconomic cost, it is imperative to correctly identify patients in the intermediate-risk category who would benefit from more aggressive treatment. A plethora of experimental and observational studies provide support that lipoprotein associated phospholipase A2 (Lp- PLA2) and secretory phospholipases A2 (sPLA2) as well as high sensitivity C-reactive protein (hsCRP) are useful biomarkers of cardiovascular risk. Particularly, Lp-PLA2) has also been addressed as pharmacological target and we are eagerly awaiting the results of ongoing phase III clinical trials. In this review we discuss the current literature regarding the pros and cons of these biomarkers.
Export Options
About this article
Cite this article as:
Moutzouri Elisavet, Tsimihodimos Vasilis and D. Tselepis Alexandros, Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/10.2174/13816128113199990307
DOI https://dx.doi.org/10.2174/13816128113199990307 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet the Editorial Board
Current Vascular Pharmacology Intracranial Collateral Flow Estimated by Color Velocity Imaging Quantification Ultrasound: A Protector of Recurrent Stroke in Patient with Carotid Stenosis?
Current Neurovascular Research Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening The Negative Influence of Socio-Technical Developments on Eating Habits and Health
Current Nutrition & Food Science Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Clinical Observation of Liver Chemistry Abnormalities in Asthmatics
Current Drug Safety Variations and Abnormalities of Major Thoracic Vascular Structures
Current Medical Imaging The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study
Vascular Disease Prevention (Discontinued) Editorial [Hot Topic:Dietary Determinants of the Metabolic Syndrome (Guest Editor: Luc Tappy Co-Editors: Jacques Delarue and Kim-Anne Le)]
Current Nutrition & Food Science An Update to Enterococcal Bacteremia: Epidemiology, Resistance, and Outcome
Infectious Disorders - Drug Targets The Concept of Depression as a Dysfunction of the Immune System
Current Immunology Reviews (Discontinued) Manipulation and Engineering of Metabolic and Biosynthetic Pathway of Plant Polyphenols
Current Pharmaceutical Design Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews The Role of Niacin in Lipid-lowering Treatment: Are we Aiming Too High?
Current Pharmaceutical Design Statins as Either Immunomodulators or Anti-Cancer Drugs: Functional Activities on Tumor Stromal Cells and Natural Killer Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Future Therapeutic Directions: New Medications and Insulin Delivery in a Changing World for Effective Diabetes Management
Current Drug Discovery Technologies The Therapeutic Potential of Stem Cells in Amyotrophic Lateral Sclerosis
Current Signal Transduction Therapy